Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Abstract Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demon...

Full description

Saved in:

Bibliographic Details
Main Authors:	Randi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, Vincent Des Portes, Andrew Stanfield, Barbara Koumaras, Gerd Rosenkranz, Alessandra Murgia, Christian Wolf, George Apostol, Florian von Raison
Format:	article
Language:	EN
Published:	Nature Portfolio 2018
Subjects:	Mavoglurant Core Studies Fragile X Mental Retardation Protein (FMRP) Repetitive Behavior Scale-Revised (RBS-R) Extension Study Baseline Medicine R Science Q
Online Access:	https://doaj.org/article/b0c86247e00a4aa7a01f18f018f9be46
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Similar Items